FFO
COGT icon

Fortitude Family Office’s Cogent Biosciences COGT Stock Holding History

Fortitude Family Office’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7K Buy
+44
New +$1.54K ﹤0.01% 1539
2025
Q2 		– Sell
-105
Closed -$629 – 2047
2025
Q1 		$629 Hold
105
– – ﹤0.01% 1070
2024
Q4 		$819 Hold
105
– – ﹤0.01% 1160
2024
Q3 		$1.13K Hold
105
– – ﹤0.01% 1086
2024
Q2 		$885 Hold
105
– – ﹤0.01% 891
2024
Q1 		$706 Buy
+105
New +$649 ﹤0.01% 919

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fortitude Family Office's COGT Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Cogent Biosciences (COGT) in Q2 2026: 44 shares worth $1.7K. The stake represents ﹤0.01% of the portfolio and ranks #1539 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in COGT as recently as Q1 2025.

Fortitude Family Office first reported a position in COGT in Q1 2024 and has held it in 6 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Fortitude Family Office held 44 shares of Cogent Biosciences worth $1.7K as of Q2 2026.
  • Cogent Biosciences was a new Fortitude Family Office position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1539 holding.
  • Fortitude Family Office first reported a position in Cogent Biosciences in Q1 2024 and has held it in 6 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.